Results 21 to 30 of about 1,612 (203)
Prospects for Droxidopa in Neurogenic Orthostatic Hypotension [PDF]
Hypertension, 2014 See related article, pp 101–107 Neurogenic orthostatic hypotension (nOH) is a debilitating disorder defined by a sustained decrease in systolic blood pressure of 20 mm Hg or in diastolic blood pressure of 10 mm Hg within 3 minutes of head-up tilt or standing.1 The disorder is associated with attenuated increases in plasma norepinephrine and peripheral
Amanda J. Ross, Julian M. Stewart
openalex +3 more sources
Financial Conflicts of Interest During Meetings of the Cardiovascular and Renal Drugs Advisory Committee [PDF]
, 2022 Context: The Cardiovascular and Renal Drugs Advisory Committee (CRDAC) of the Food and Drug Administration (FDA) reviews safety and efficacy data for cardiovascular and renal drugs, ultimately making recommendations to the Commissioner of Food and Drugs ...
Ahlander, Joseph +7 more
core +2 more sources
Accidental Overdose of Droxidopa in Parkinson's Disease‐related Orthostatic Hypotension [PDF]
Movement Disorders Clinical Practice, 2016 Addie Patterson, Christopher W. Hess
openalex +3 more sources
Neurogenic orthostatic hypotension – management update and role of droxidopa
Therapeutics and Clinical Risk Management, 2015 Orthostatic hypotension (OH) is defined as a significant decrease in blood pressure (BP) during the first 3 minutes of standing or a head up on a tilt table. Symptoms of OH are highly variable, ranging from mild light-headedness to recurrent syncope.
Vijay K. Sharma, Joy Vijayan
openalex +4 more sources
Orthostatic hypotension: An overlooked but clinically decisive entity
Journal of the Indian Academy of Geriatrics, 2022 Orthostatic hypotension (OH) is defined as a drop of >20 mm Hg of systolic or >10 mm Hg of diastolic blood pressure (BP) within 3 min of standing from lying position. It is a common geriatric syndrome caused by impaired orthostatic response of BP.
Gunja Jain +3 more
doaj +1 more source
Chemistry, 2023 Tyrosine-containing pharmaceuticals’ (TPh) potential to inhibit SARS CoV-2 3-chymotrypsin-like proteases (3CLpro) and nonstructural protein 16 (NSP16) has been explored using docking studies, molecular dynamics simulations, and density functional theory.
Mohamed R. Elamin +2 more
doaj +1 more source
Ampreloxetine Versus Droxidopa in Neurogenic Orthostatic Hypotension: A Comparative Review. [PDF]
Cureus, 2023 Neurogenic orthostatic hypotension (nOH) is a disabling problem of autonomic dysfunction in patients with Parkinson's disease, which is associated with poor quality of life and higher mortality rates. The purpose of this literature review was to explore and compare the efficacy and safety of droxidopa (an existing treatment) and ampreloxetine (a newer ...
Hoxhaj P +12 more
europepmc +3 more sources
Emerging pharmacological strategies for the treatment of fibromyalgia [PDF]
, 2017 Fibromyalgia (FM) has been described as a chronic clinical condition related to multisensory hypersensitivity presenting with a complex of symptoms dominated by chronic widespread pain associated with the existence of a range of co-morbidities, such
Lawson, Kim
core +1 more source
Journal of Clinical and Translational Science, 2018 OBJECTIVES/SPECIFIC AIMS: To describe adverse behavioral symptoms attributed to droxidopa therapy for neurogenic orthostatic hypotension (nOH). METHODS/STUDY POPULATION: BACKGROUND: Droxidopa, a norepinephrine (NE) precursor, improves symptoms of nOH by ...
Katherine McDonell +4 more
doaj +1 more source
Potential drug therapies for the treatment of fibromyalgia [PDF]
, 2016 INTRODUCTION: Fibromyalgia (FM) is a common, complex chronic widespread pain condition is characterized by fatigue, sleep disturbance and cognitive dysfunction.
Lawson, Kim
core +1 more source